Prospects for development of group purchasing organizations (GPOs) in China within the context of national centralized drug procurement-Reference-Cited by-同舟云学术

Prospects for development of group purchasing organizations (GPOs) in China within the context of national centralized drug procurement

Published:2020-06-30 Issue:3 Volume:14 Page:145-148
ISSN:1881-7831
Container-title:Drug Discoveries & Therapeutics
language:en
Short-container-title:DD&T

Author:

Chen Minxing¹,Cong Lixuan¹,He Jiangjiang¹,Yang Yan¹,Xu Yuan¹,Tang Mi¹,Jin Chunlin¹

Affiliation:

1. Shanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai, China.

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.jstage.jst.go.jp/article/ddt/14/3/14_2020.03024/_pdf

Reference15 articles.

1. 1. HSCA. What is a group purchasing organization? https://www.supplychainassociation.org/about-us/faq/ (accessd January 5, 2020).

2. 2. Weinstein BL. The role of group purchasing organizations (GPOs) in the US medical industry supply chain. Estudios De Economia Aplicada. 2006; 24:789-801.

3. 3. De Economia Aplicada. 2006; 24:789-801. HSCA. HSCA 2017 Annual Value Report. http://www.insidehsca.com/2017/01/31/2017-annual-value-report/ (accessd March 1, 2020).

4. 4. Young GJ, Nyaga GN, Zepeda ED. Hospital employment of physicians and supply chain performance: An empirical investigation. Health Care Manage Rev. 2016; 41:244-255.

5. 5. Zepeda ED, Nyaga GN, Young GJ. Supply chain risk management and hospital inventory: Effects of system affiliation. J Oper Manag. 2016; 44:30-47.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of China’s National Centralized Drug Procurement Policy on pharmaceutical enterprises’ financial performance: a quasi-natural experimental study;Frontiers in Public Health;2023-11-03

2. Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study;BMJ Open;2023-07

3. The impact of pharmacist intervention on the intravenous-to-oral switch therapy of proton pump inhibitors in cardiovascular surgery;Expert Opinion on Drug Safety;2023-02-02

4. Can the Profitability of Medical Enterprises Be Improved After Joining China's Centralized Drug Procurement? A Difference-in-Difference Design;Frontiers in Public Health;2022-02-01

5. Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms’ R&D Investment in China? An Event Study Approach;International Journal of Environmental Research and Public Health;2021-11-16